

QIANG MA

Partner

Fangda Partners

+86 755 8159 3999

qiang.ma@fangdalaw.com



PRACTICE AREAS

MR. MA FOCUSES ON M&A, PRIVATE EQUITY INVESTMENT AND CAPITAL MARKETS.

REPRESENTATIVE MATTERS AND CASES

M&A/Private Equity Investment

- Represented TCL Technology (000100.SZ) and TCL CSOT, as their leading legal counsel, in the strategic acquisition of the Samsung's LCD business in China for US\$1.08 billion
- Represented TCL CSOT in its joint venture with San'an Semiconductor for Micro-LED display technology business
- Represented TCL Technology Investment in its sale of 100% of the shares in TCL Educational Web to Minsheng Education (01569.HK)
- Represented Shenzhen Major Industrial Investment Group, as one of the investors (with other investors including China Ping An and Zhuhai Huafa) to participate in the bankruptcy restructuring of Peking University Founder Group Co., Ltd. and to acquire the controlling stake in Founder Microelectronics through the bankruptcy restructuring process
- Represented Mindray (300760. SZ) in its asset restructuring of animal medical business
- Represented Mindray (300760. SZ) in its pre-IPO financing of more than RMB 5.9 billion with over 20 investors

- Represented LifeTech (01302.HK), a leading global provider of medical devices for cardiovascular and cerebrovascular micro-invasive intervention, and provided legal advice and transaction services on multiple strategic acquisitions and restructure transactions, including the spin-off and post-spin-off equity financing of its bioresorbable iron stent business
- Represented Nayuki, a well-known tea drinks brand in China, in its series C financing of around US\$100 million, involving PAG as an investor
- Represented Baoneng Real Estate, and provided legal advice and transaction services in connection with an acquisition of control over a real estate in Shanghai and the related dispute over control of the company, for a transaction consideration of approximately RMB 15 billion
- Represented multiple active RMB or USD investors, including CMC Capital, CITICPE, CMBI etc., on their several fund investment projects in the PRC or overseas, involving industries including consumer goods, medical health and TMT, recent representative transactions include:
 - Represented CMC Capital in the equity financing of Taishan Beer, involving an aggregate financing amount of approximate RMB 660 million
 - Represented CMC Capital in the equity financing of Shiyue Daotian, a leading agricultural enterprise in China, with several brands such as Shiyue Daotian and Chaihuo Dayuan, involving an aggregate financing amount of approximate RMB 700 million
 - Represented CMBI International in its Series B+ equity investment in J&T Global Express Limited, involving an aggregate transaction price of US\$1.8 billion
 - Represented CMBI International in its Series C equity investment in Dmall Inc
 - Represented CPE in its equity investment in Probe Technology and its concurrent sale of controlling equity interest in Bioptimal International Pte. Ltd., a Singaporean medical devices company for critical care business, to PROBE

Capital Markets

- Represented China Resources and provided strategic legal advice and transaction services in the acquisition of Vanke by external investors, the proposed share issue by Vanke to acquire assets of Shenzhen Metro, the corporate governance disputes with Vanke management, and the sale of approximately 15.31% shares in Vanke to Shenzhen Metro for approximately RMB 37.2 billion

- Represented Mindray (300760. SZ), a leading global provider of medical devices and solutions, in its privatization, delisting, post-delisting restructuring from an American exchange, and IPO and listing of A Shares in GEM of Shenzhen Stock Exchange, which was the largest ever A-Share medical equipment project listing
- Represented iRay Technology (688301.SH) in its IPO in Sci-tech Innovation Board of Shanghai Stock Exchange, which marks the largest IPO project in the special equipment manufacturing industry of Sci-tech Innovation Board and the first A-share listed company of medical core-component equipment as of now
- Represented AUPU Group (HKSE:00477) in its privatization and delisting from the Hong Kong Stock Exchange and in its IPO and listing of A shares (603551. SH)
- Represented as legal counsel to Huatai United Securities as the sole sponsor and underwriter in connection with several IPOs and listings on the Sci-tech Innovation Board of Shanghai Stock Exchange, including Vazyme Biotech
- Represented BTR, one of the leading enterprises in the global lithium battery anode material industry, in its IPO and listing on the NEEQ Selected Market, which constitutes the largest raising amount in the NEEQ Selected Market as of now
- Represented a consortium of investors in the voluntary conditional cash offer of HK\$3.857 billion for the acquisition of all shares in Clear Media Ltd. (0100. HK), which was the largest operator of bus shelter advertising panels in the PRC and a company listed on the Hong Kong Stock Exchange
- Represented OOCL in the acquisition by COSCO Shipping and SIPG of all OOCL issued shares through a cash offer of approximately HK\$49 billion

OTHER INFORMATION

Education

- Southwest University of Political Science & Law, Master of Laws
- Southwest University of Political Science & Law, Bachelor of Laws

Professional Qualification

- Admitted to practice in the PRC

Professional Background

Before joining Fangda Partners, Mr. Ma worked at another top PRC law firm for several years.